Navigation Links
Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program
Date:8/29/2011

s a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Caution Regarding Forward-Looking Information

To the extent any statements made in this document contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information as defined under applicable Canadian securities legislation (collectively, "forward-looking statements").

This press release may contain forward-looking statements. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements, which include statements regarding future repurchases under the securities repurchase program, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the SEC and risks and uncertainties as detailed from time to time in Valeant's filings with the SEC and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of t
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Cadence Fitness & Health Center has been certified ... Association, a non-profit organization assisting medically integrated health and ... Fitness & Health Center is the only certified fitness ... Chicagoland area. "The certification means the Cadence ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... PHOENIX, Sept. 4 Zila, Inc.,s (Nasdaq: ZILA ... of,abnormalities which can lead to oral cancer, has been ... of Cetuximab (ERBITUX(R)), a,leading cancer therapeutic for head and ... and distributed by Bristol-Meyers Squibb (NYSE:,BMY). The NIH ...
... Meets Primary and All Secondary Endpoints, San ... NGSX ), a biopharmaceutical company focused on developing ... from,its second pivotal study of NGX-4010, the Company,s ... -- in patients with postherpetic,neuralgia (PHN). The study, ...
Cached Medicine Technology:Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 2Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 3NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 2NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 3NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 4NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 5NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 6NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 7
(Date:4/18/2014)... The Gerontologist reports that among ... a decrease in anxiety about death and increases in ... lives. In particular, listening to gospel music is associated ... increase in sense of control. , These associations are ... individuals of both low- and high-socioeconomic status. , The ...
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2
... Will Educate Families And Increase Landlord ... ... Women and The Sherwin-Williams Company are pleased to announce "NOT,IN OUR ... arising from poor maintenance and neglect and to encourage property,owners and ...
... Sept. 10 Maxim Health Systems today,announced it will ... 2007. Maxim will provide flu shots nationwide through more,than ... http://www.FindAFluShot.com, helps users find a convenient location for,vaccination ... on the site to,obtain times and locations for clinics. ...
... DIEGO, Sept. 10 Conflict is an issue that ... to have little preparation on,how to communicate effectively to ... school bullies. These rivalries can be harmful,to children, whether ... violent behavior, and anger management issues. It is ...
... A lesser known,antibiotic-resistant bacteria is a growing ... are seeing the potentially deadly staph,infection known as ... South Texas was one of the first ... since become a hot bed for the infection. ...
... Breathe Act, MINNEAPOLIS, Sept. 10 Today ... to educate and excite Minnesotans about the,Freedom to ... into effect,on October 1. The new law will ... private clubs. Called Fresh Air, the,multimedia campaign is ...
... ... the Advancement of Science, PHILADELPHIA and LONDON, Sept. 10 ... ; TSX: TOC) and,leading provider of information solutions to the ... Laureates,-- researchers likely to be in contention for Nobel honors ...
Cached Medicine News:Health News:National Council of Negro Women (NCNW) Partners With Sherwin-Williams to Target Lead Risks in Neglected Housing 2Health News:Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide 2Health News:Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide 3Health News:Tips for Parents: Teaching Children to Resolve Conflicts 2Health News:South Texas Doctors Report More Severe Cases of Community Staph 'Super Bug' Hospitalizing Children 2Health News:Fresh Air Campaign to Showcase Minnesotans' Love of Smoke-Free Air 2Health News:Thomson Scientific Predicts Nobel Laureates 2Health News:Thomson Scientific Predicts Nobel Laureates 3Health News:Thomson Scientific Predicts Nobel Laureates 4
This fume hood features a one-piece shell molded of polyethylene with a clear acrylic panel that slides on inside tracks. It can be set in an open, closed or intermediate position....
These handy dispensers save space and organize gloves in labs and next to hand washers. Clear acrylic. Many other sizes and custom configurations available....
... Sledge Microtome is ideal for sectioning of specimens ... Specimen rise is automatic and accurate with ... in increments of 2 microns. Will accommodate ... Vibratomes Freezing Stages , ...
... The Professional Gold Package ... your laboratory. The package includes ... and automated system, starter package ... v-block adapter, specimen mounts 1/2" ...
Medicine Products: